InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,247.23
(
0.36%
)
Post# of 252186
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119839
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 167170

Wednesday, 08/06/2014 5:13:36 PM

Wednesday, August 06, 2014 5:13:36 PM

Post# of 252186
PTLA red flag: Management wants to amend the SAP for the phase-3 APEX study of Betrixaban, despite the fact that the trial is 50% enrolled. Sounds like they don’t think the trial will hit the primary endpoint on the total population and are already trying to make an argument for subset data. (Source: Today's 2Q14 CC.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up